Please login to the form below

Not currently logged in
Email:
Password:

Guidance on joint working

The ABPI has published new guidelines on joint working between the pharma industry and the NHS, providing greater clarity of what is allowed under the Code of Practice

The Association of the British Pharmaceutical Industry (ABPI) has published new guidelines on joint working between the pharma industry and the NHS, designed to provide a clear framework for collaborative working and offer greater clarity of what is allowed under the Code of Practice.

The breadth of projects covered by guidance is likely to be of significant scale and duration, and emphasis will be placed on delivering patient benefit using pooled resources.

ABPI member companies, the Medicines and Healthcare products Regulatory Agency (MHRA) and the Department of Health helped to develop the guidance along with a number of Royal Colleges and other NHS representatives.

The NHS Confederation, NHS Alliance and the National Association of Primary Care (NAPC) have welcomed the guidance.

"The NHS Alliance welcomes this new ABPI guidance. It is quite right that all parties that undertake joint working – patients, the NHS and the pharmaceutical companies – gain from such endeavour. The proposed benefits to all need to be understood and agreed at the outset," said a spokesman for the NHS Alliance.

"This comprehensive guidance should assist both NHS organisations and pharmaceutical companies to articulate these benefits in a more open and transparent manner. It is helpful that the MHRA and a number of Royal Colleges have been involved during the consultation and are supportive of the guidance."

Commenting on the guidelines, the ABPI said: "This new guidance should give companies reassurance when working with NHS organisations to benefit patient care."

Further information on the guidance can be found in the ABPI guidance notes (pdf).

9th March 2009

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics